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ABSTRACT
To determine the sensitivity and speciﬁcity of Focus HerpeSelect ELISAs, sera or plasma samples from
women aged 18–55 years were collected in ten cities from eight countries and tested by HerpeSelect
HSV-1 ELISA (Focus-HSV-1) and by HerpeSelect HSV-2 ELISA (Focus-HSV-2). Sera with Focus-HSV-
2-positive results were retested; 94% of the 3617 samples retested were positive. A subset of sera from
each site was then selected, based on the HSV-2 results, and tested by Western blot (WB). The sensitivity
and speciﬁcity were determined with samples from ten sites (n ¼ 967) for Focus-HSV-1 and from seven
sites (n ¼ 675) for Focus-HSV-2. Focus-HSV-1 and WB results were concordant (both negative or both
positive) for 97% of samples, with 99% sensitivity and 77% speciﬁcity. Specimens from Songkla,
Thailand had 84% concordance with WB results for HSV-1, while three other sites had 100%
concordance. Concordance of Focus-HSV-2 and WB was 92%, with 97% sensitivity and 89% speciﬁcity.
Ibadan, Nigeria had 78% concordance. Focus-HSV-2 sensitivity and speciﬁcity in sites other than Ibadan
were 97% and 93%, respectively. Raising the positive cut-off index value for HSV-2 from 1.1 to
3.5 yielded a sensitivity of 90% and a speciﬁcity of 96%. A sensitivity of 90% and a speciﬁcity of 98%
were achieved for sites other than Nigeria with the higher cut-off. In summary, the sensitivity and
speciﬁcity of the Focus-HSV-1 and Focus-HSV-2 tests varied by site. Performance data generated in one
area may not be applicable to other populations.
Keywords ELISA, herpes simplex virus, serological tests
Original Submission: 25 April 2003; Revised Submission: 29 July 2003; Accepted: 21 August 2003
Clin Microbiol Infect 2004; 10: 530–536
INTRODUCTION
Herpes simplex virus infections caused by type 1
(HSV-1) and type 2 (HSV-2) are worldwide in
distribution. While HSV-1 can cause both oral and
genital infections, HSV-2 is transmitted almost
exclusively sexually and is the major cause of
genital herpes. A recent review summarised data
from a large number of age-speciﬁc HSV-1 and
HSV-2 seroprevalence studies conducted in a
variety of populations around the world [1]. In
1990, Nahmias et al. [2] reported data obtained
with a single serological method that assessed the
prevalence of HSV-1 or HSV-2 antibodies in
different geographical areas worldwide. These
studies showed a great range in HSV-2 seroprev-
alence within continents, and across subpopula-
tions. Type-speciﬁc seroprevalence studies aid in
determining the regional public health impact of
genital herpes in different populations. The accu-
rate assessment of HSV-1 and HSV-2 antibody
status is also key to developing population-based
treatment and disease prevention strategies [3–5].
With growing evidence of the role of genital
herpes infection in the spread of HIV [6], such
strategies have taken on a new urgency.
Over the past 15 years, tests for type-speciﬁc
antibody to HSV-1 or HSV-2 have been developed
[7]. Several of these tests have been validated in
studies of patients with clinically and virological-
ly documented infections. These are the standards
for developing performance data on newer type-
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speciﬁc antibody tests, and include the glycopro-
tein G (gG) monoclonal antibody-blocking ELISA
[8], the gG immunodot enzyme assay [9,10] and
Western blot (WB) [11]. Commercial tests based
on the type-speciﬁc HSV gG have been developed
and their performance characteristics determined
against reference assays. These tests vary consid-
erably in their sensitivity and speciﬁcity [7]. Such
variation can make it difﬁcult to compare sero-
prevalence studies based on different serological
methods.
New type-speciﬁc ELISAs based on recombin-
ant gG-1 and recombinant gG-2 have now been
developed and have been approved by the US
Food and Drug Administration for use in adult
populations. These new ELISAs have high repor-
ted sensitivity and speciﬁcity [12,13], and are
available widely around the world. This study
was designed to compare these ELISAs with a
well-accepted standard test, WB, on banked sera
and plasma from widespread geographical areas.
While the emphasis was on HSV-2 results, it was
also possible to compare HSV-1 results in these
samples.
MATERIALS AND METHODS
Samples
Blood samples were collected from women aged ‡ 15 years as
part of a broader seroprevalence study [14] and separated by
centrifugation at the collection site. Separated sera or plasma
were split into aliquots, frozen at ) 20 C and shipped to the
International Agency for Research on Cancer (Lyon, France)
for storage at ) 20 C or ) 80 C. Samples were collected with
informed consent and with approval of the Institutional
Review Board at the International Agency for Research on
Cancer and local institutional review boards in each country.
Sites were: Concordia, Argentina; Guanacaste, Costa Rica;
Busan, Korea; Cuernavaca, Mexico; Ibadan, Nigeria; Barcelona,
Spain; Lampang, Thailand; Songkla, Thailand; Hanoi, Viet-
nam; and Ho Chi Minh City, Vietnam. Plasma or sera were
shipped, frozen, to the central testing laboratory in Seattle, in
site-speciﬁc sets, between June 2000 and January 2001, and
were stored at ) 20 C. Samples were allowed to thaw
overnight at + 4 C before testing.
Internal control sera included a pool of sera with only HSV-
1 antibodies, as determined by WB [11], and a pool with only
HSV-2 antibodies by WB. Both pools were obtained from the
University of Washington Virology Laboratory (UWVL),
Seattle, Washington.
HSV ELISA
Samples were tested in Seattle by HSV-1 ELISA IgG and by
HSV-2 ELISA IgG (MRL, now Focus Technologies; Cypress,
CA, USA). The name of the tests has since been changed by
Focus Technologies to HerpeSelect. For clarity, the tests are
referred to as Focus-HSV-1 or Focus-HSV-2 in this paper. Each
sample was vortexed, and 2.5 lL was diluted 1 : 101 into
dilution wells containing 250 lL of sample diluent (Focus
Technologies). Kit controls, including high positive, low
positive, negative and calibrator sera, were also diluted
1 : 101. The UWVL HSV-1 internal positive control was added
to each HSV-1 plate, and the UWVL HSV-2 positive control
was added to each HSV-2 plate. The samples in the dilution
plate were then mixed and added to Focus HSV-1 or HSV-2
reaction plates using an eight-channel pipetter. Plates were
read with an EL-340 plate reader and KC4 software (BioTek
Instruments; Winooski, VT, USA). Optical density values were
adjusted for background according to instrument instructions,
and then exported to Microsoft Excel ﬁles. Index values were
then calculated according to kit instructions by dividing the
adjusted sample optical density by the mean of the three
calibrators’ adjusted optical density values. Samples with
index values > 1.1 were recorded as positive, and those with
index values < 0.9 were recorded as negative. Values between
0.9 and 1.1 were recorded as equivocal.
Samples that were positive for HSV-2 antibodies were
retested in Seattle by Focus-HSV-2 ELISA, and the results were
compared to determine test reproducibility. Sensitivity and
speciﬁcity determinations, and analyses of the effect of index
value cut-off on test speciﬁcity, were based on the ﬁrst test
values. Performance calculations were made using WB as the
standard. Sensitivity was calculated as the number of true-
positive (TP) samples divided by the sum of the TP plus false-
negative (FN) samples; speciﬁcity was true-negative (TN)
divided by TN + false-positive (FP); negative predictive value
(NPV) was TN ⁄ (TN + FN); positive predictive value (PPV)
was TP ⁄ (TP + FP). All ﬁnal values were multiplied by 100 and
expressed as percentages.
Western blot
WB testing was performed on a subset of 100 samples from
each site; sera were preselected at the International Agency for
Research on Cancer, according to the Focus-HSV-2 results
provided by the Seattle laboratory, so that about half were
positive for HSV-2 and about half were negative. Focus-HSV-1
status was not considered in sample selection for this sub-
study. Samples were coded and sent in groups, by site, to the
diagnostic virology laboratory in Seattle (UWVL) for WB
testing, which was performed blind to Focus ELISA results.
The results of WB tests were sent electronically by UWVL to
one of the co-authors (JN or NB) and merged with the Focus
testing results. These results were then sorted with the built-in
Microsoft Excel ﬁlter function to compare WB and Focus test
outcomes for HSV-2. Comparisons were also made for HSV-1
outcome by Focus-HSV-1 or WB on these samples, despite the
fact that the samples were preselected according to HSV-2
antibody status only.
Internal proﬁciency testing of WB was performed at
intervals during the study by withdrawing 200 lL of samples
selected by random number tables into a second tube. These
internal repeat samples were coded and labelled to resemble
other test samples and were tested by WB without knowledge
that they were internal controls. Codes were broken and
reproducibility determined at the end of the study. Of 60 total
blinded internal repeats, 98% had the same result for HSV-1.
Thus, all HSV-1 results from all sites were from acceptable WB
runs. Two sets of 11 and 22 sera, respectively, were run, with
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100% (11 of 11) and 95% (21 of 22) concordance in HSV-2
results. The single discordant sample was HSV-2 in the ﬁrst
test; this had an atypical HSV-2 pattern in the second test. A
third set of 22 samples had 17 (77%) results reproduced for
HSV-2, an unacceptably low reproducibility rate. As a result,
the WB HSV-2 data for sera tested during the time the internal
repeats were performed were considered invalid. The WB runs
that failed HSV-2 reproducibility testing were probably caused
by differences in subjective reading of the WB proﬁles for
HSV-2. As two separate antigen preparations are used for
HSV-1 and HSV-2, reproducible results for one antibody type
do not predict those for the other type. Thus, all testing for
HSV-1 was considered to be reliable, while WB results for
HSV-2 from Lampang, Barcelona and Hanoi were invalid
for use as a validation measure.
RESULTS
Seroprevalence of HSV-1 and HSV-2
In total, 11 060 samples were tested. Age-speciﬁc
and site-speciﬁc HSV-1 and HSV-2 seropreva-
lence data have been presented previously for all
sites except Nigeria [15]. Site-speciﬁc seropreva-
lence was determined by Focus ELISA after
excluding equivocal results. HSV-1 seropreva-
lence was very high (93–99%) for all sites except
Songkla, which had 65% HSV-1 seroprevalence.
HSV-2 site-speciﬁc seroprevalence rates were
substantially lower than those of HSV-1. Overall,
3641 (33%) of the 11 060 samples tested were
positive for HSV-2 (median 32%; range 10–62%).
Barcelona had the lowest HSV-2 seroprevalence,
at 10% [15]. Nigeria had the highest HSV-2
seroprevalence, at 62%.
The proportion of sera with equivocal results
by Focus ELISA was very small in this large
study. For HSV-1, 78 (0.7%) of 11 060 results were
equivocal (range 0–5% across sites). One site,
Songkla, had a seven-fold higher rate (5%) of
equivocal test results for HSV-1 than the total
group. The Focus HSV-2 test gave deﬁnitive
results for > 98% of samples; 167 (1.5%) of
11 061 were equivocal (range 0.8–3.2% across
sites). Nigeria had the highest proportion of
samples with equivocal index values for HSV-2
(3.2%; 41 of 1268).
Reproducibility of Focus-HSV-2 results
Samples giving positive Focus-HSV-2 results
were retested by Focus-HSV-2 at a later time to
determine the reproducibility of the test. Of 3641
positive samples, 3617 (99%) were available for
repeat testing. Of these, 3402 (94%) were positive,
85 (2%) were equivocal and 130 (4%) were
negative on repeat testing for HSV-2.
Focus-HSV-1 vs. Western blot
Table 1 shows data relating to the concordance of
the Focus-HSV-1 test result when compared to
HSV-1 antibody detection by WB. Samples with
equivocal results in either Focus or WB tests were
excluded, giving 969 evaluable pairs. Of these,
concordant results (i.e., both tests negative or both
positive) for HSV-1 were obtained for 939 (97%)
pairs. Across the ten sites, the two tests were
concordant for HSV-1 in 84–100% of samples.
Songkla, Thailand had the lowest HSV-1 concor-
dance (84%). Of the 14 sera from Songkla with
discordant results, most (n ¼ 9; 64%) were Focus-
HSV-1-positive, but WB-negative. Overall, across
all sites, the sensitivity of the Focus-HSV-1 test was
99% (range 91–100), the speciﬁcitywas 78% (range
67–100), the NPVwas 80%, and the PPV was 98%.
Focus-HSV-2 vs. Western blot
HSV-2 concordance between Focus-HSV-2 and
WB was calculated for 675 samples from seven
sites (Table 2). This ﬁgure excluded samples
(n ¼ 20) yielding equivocal results by Focus-
HSV-2, WB, or both tests. Concordance ranged
Table 1. Results of testing for HSV-1 antibodies by Focus-
HSV-1 and Western blot
Site na
Outcome of tests
(Focus ⁄WB)a
Concordance
(%)
Sensitivity
(%)
Speciﬁcity
(%)– ⁄ – – ⁄+ + ⁄ – + ⁄+
Concordia,
Argentina
99 1 1 0 97 99 99 100
Guanacaste,
Costa Rica
98 4 2 2 90 96 98 67
Busan,
Korea
100 6 1 1 92 98 99 86
Cuernavaca,
Mexico
100 4 0 0 96 100 100 100
Ibadan,
Nigeria
100 0 0 0 100 100 100 NA
Barcelona,
Spain
85 5 0 1 79 98 99 100
Lampang,
Thailand
98 5 2 2 89 97 98 71
Songkla,
Thailand
90 26 5 9 50 84 91 74
Hanoi,
Vietnam
99 0 0 0 99 100 100 100
Ho Chi
Minh City,
Vietnam
100 2 2 0 96 98 98 100
Total 969 53 13 15 888 97 99 78
aAdjusted to exclude samples that were equivocal by Focus (n ¼ 8) or WB (n ¼ 7).
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from 78% to 97% across sites, with an overall
concordance of 92%. Of the 51 discordant sam-
ples, 43 (84%) were Focus-HSV-2-positive but
WB-negative. This ﬁgure was inﬂuenced by the
high discordance rate among samples from
Nigeria. This one site had discordant results for
21 (22%) of 97 samples, all of which were Focus-
HSV-2 false-positive. The sensitivity of the Focus-
HSV-2 test, overall, was 97%, the speciﬁcity was
89%, the PPV was 86%, and the NPV was 98%.
The sensitivity and speciﬁcity for all sites except
Nigeria were 97% and 93%, respectively, with an
NPV of 97% and a PPV of 92%.
Index values of Focus-HSV-2 samples
Of 313 Focus-HSV-2-positive results, 43 (14%)
were negative by WB and 270 were positive by
WB. The median index value of the 270 samples
that were positive by both Focus-HSV-2 and WB
was 10.0. Median values for conﬁrmed positive
sera varied from 5.9 to 14.2 (Table 3). In contrast,
the median index value of the 43 Focus-HSV-
2-positive, WB-negative samples was 2.5, with a
range of 1.5–3.0 (Table 3). Nigeria had the highest
median index value (3.0) for unconﬁrmed sera,
whereas Korea and Mexico had median index
values of 1.5. Eleven (19%) of the 43 unconﬁrmed
specimens had index values in the HSV-2 high
positive range, deﬁned in the kit insert as values
above 3.5.
As shown in Fig. 1, index values for conﬁrmed
vs. unconﬁrmed positive samples had consider-
able overlap. Site-speciﬁc index values were
signiﬁcantly higher in conﬁrmed samples than
Table 2. Results of testing for HSV-
2 antibodies by Focus-HSV-2 and
Western blot
Site na
Outcome of tests
(Focus ⁄WB)a
+ ⁄+
Concordance
(%)
Sensitivity
(%)
Speciﬁcity
(%)
NPV
(%)
PPV
(%)– ⁄ – – ⁄+ + ⁄ –
Concordia,
Argentina
97 55 2 4 36 94 94 93 96 90
Guanacaste,
Costa Rica
94 51 0 3 40 97 100 94 100 93
Busan,
Korea
97 52 2 3 40 95 95 95 96 93
Cuernavaca,
Mexico
94 47 1 4 42 95 98 92 98 95
Ibadan,
Nigeria
97 48 0 21 28 78 100 70 100 57
Songkla,
Thailand
98 51 0 3 44 97 100 94 100 94
Ho Chi Minh City,
Vietnam
98 50 3 5 40 92 93 91 94 89
Total 675 354 8 43 270 92 97 89 98 86
aAdjusted to exclude samples that were equivocal by Focus-HSV-2 (n ¼ 11), by WB (n ¼ 7), or by both (n ¼ 2).
Table 3. Comparison of Focus-HSV-2 index values of
samples either conﬁrmed or not conﬁrmed by Western blot
Site
Not conﬁrmed
by WB Median
index value
Conﬁrmed by
WB Median
index value p valuea
Concordia, Argentina 1.6 5.9 0.004
Guanacaste, Costa Rica 2.7 11.3 0.016
Busan, Korea 1.5 9.2 0.022
Cuernavaca, Mexico 1.5 9.0 0.003
Ibadan, Nigeria 3.0 7.8 < 0.001
Songkla, Thailand 2.6 14.2 0.07
Ho Chi Minh City, Vietnam 1.6 11.8 0.001
Total combined 2.5 10.0 < 0.001
aMann–Whitney rank sum test.
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Fig. 1. Index values for Focus-HSV-2-positive results not
conﬁrmed by WB (left-hand bar in each pair) and index
values for Focus-HSV-2 results conﬁrmed as positive by
WB (right-hand bar in each pair) are presented by location.
The symbols indicate outliers. Median values are repre-
sented by the black horizontal bars in the boxes, and each
box represents the interquartile range. The numbers of
samples are given for each group; the number of samples
not conﬁrmed by WB is generally much lower than the
number conﬁrmed by WB.
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in unconﬁrmed samples (p < 0.05) for all sites
except Songkla (p 0.07).
Effect of cut-off increase on speciﬁcity and
sensitivity
To increase the speciﬁcity of the Focus test (i.e.,
decrease false-positive Focus-HSV-2 results), the
effect of changing the HSV-2-positive cut-off
value from the suggested > 1.1 to the high positive
value of > 3.5 was tested (Table 4). This resulted
in increased speciﬁcity, but decreased sensitivity,
in all sites except Songkla, Thailand and Guana-
caste, Costa Rica. Overall, sensitivity with the
> 3.5 cut-off was 90% (a reduction from 97% with
the > 1.1 cut-off), but speciﬁcity was increased
from 89% to 96% (Table 4).
DISCUSSION
This paper reports on a large HSV-1 and HSV-2
seroprevalence study of women in ten cities in
eight countries around the world. Age-speciﬁc
HSV prevalence has been reported elsewhere for
nine of these sites [14,15]. For this study, the
performance of the Focus-HSV-1 and Focus-
HSV-2 ELISA tests was assessed in a subset of
specimens from a wide geographical distribution
by comparing results with those obtained by
WB.
HSV-1 test results were concordant in 97% of
the 967 samples tested by both Focus-HSV-1 and
WB. The majority of discordant results (18 of 28)
came from the two sites in Thailand—Songkla
and Lampang—and most of these results (11 of
18) were Focus-HSV-1 positive but WB negative.
Songkla also had the lowest seroprevalence for
HSV-1 (65%) and the highest rate of equivocal
tests for HSV-1 (10%). Repeat testing in our
laboratory and by Focus Technologies revealed
the same rate of discordance, suggesting a geo-
graphical difference in Focus-HSV-1 and ⁄ or WB
performance rather than operator artifact. Alter-
natively, specimen mix-up in samples sent for WB
could not be ruled out. Overall, speciﬁcity for
HSV-1 was difﬁcult to assess, because only 26 sera
from sites outside Thailand were seronegative for
HSV-1 by WB. Of these 26 sera, 22 were also
negative by Focus-HSV-1 (85% speciﬁcity; > 99%
PPV).
Comparison of HSV-2 results obtained with the
two different tests revealed an overall concor-
dance of 92%. As with HSV-1 testing, most of the
discordant sera (n ¼ 51) were positive by Focus-
HSV-2, but negative by WB (84%; 43 ⁄ 51). Nota-
bly, half of the false-positive sera (21 of 43) were
from a single site, Nigeria. Focus-HSV-2 speciﬁc-
ity for Nigeria was only 70%, while the speciﬁcity
for other sites was 93% (PPV ¼ 90%; Table 2). As
with discordant sera for HSV-1, specimen or
labelling confusion cannot be ruled out. All sera
positive initially by Focus-HSV-2 were thawed
and retested by Focus-HSV-2. All of the 43
subjects with false-positive Focus-HSV-2 results
were positive by repeat Focus-HSV-2 testing.
Thus, operator error in performing the ELISA on
these sera seems unlikely, since the results were
reproduced later from the same samples. Oper-
ator error in a very sensitive ELISA may occur by
splashing during dilution of sera or during
transfer of diluted sera to test plates. It was found
that as little as 0.5 lL of added positive serum
Table 4. Sensitivity and speciﬁcity
of Focus-HSV-2 using 3.5 index
value cutoff
Site n
Outcome of tests
(Focus ⁄WB)a
+ ⁄+
Concordance
(%)
Sensitivity
(%)
Speciﬁcity
(%)
NPV
(%)
PPV
(%)– ⁄ – – ⁄+ + ⁄ –
Concordia,
Argentina
97 59 8 0 30 92 78 100 96 90
Guanacaste,
Costa Rica
94 53 0 1 40 99 100 98 100 93
Busan,
Korea
97 54 8 1 34 91 81 98 96 93
Cuernavaca,
Mexico
94 50 5 1 38 94 88 98 98 95
Ibadan,
Nigeria
97 60 2 9 26 89 93 87 100 57
Songkla,
Thailand
98 53 0 1 44 99 100 98 100 94
Ho Chi Minh City,
Vietnam
98 54 5 1 38 92 88 98 94 89
Total 675 383 28 14 250 94 90 96 98 86
aSamples with index values > 1.1 but < 3.5 are included in this table as Focus-negative.
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(index value 8.8) could convert a negative well to
low positive (data not shown).
At least two explanations for the concentration
of false-positive results in Nigerian samples are
plausible. First, the WB test could be false-negat-
ive. The Focus-HSV-2 assay is more sensitive than
WB in detecting early seroconversion [16], and
may be more sensitive for low-titre sera. While
the incidence rate of HSV-2 is unknown among
the study population, HSV-2 seroprevalence for
Nigeria was 62%, suggesting that seroconversion
among Nigerian women is not a rare event. If the
Nigerian population had a preponderance of
seroconverters compared with the other sites, this
greater sensitivity might be revealed selectively.
Another possible explanation for the low spe-
ciﬁcity of the Focus-HSV-2 test in Nigeria com-
pared with other sites is strain variation.
Although gG-2 appears to be fairly well con-
served [17], strains from Africa have not been
sequenced. It is possible that the Focus assay
detects antibodies to strain-speciﬁc gG epitopes
that are not present in the WB antigen mixture.
Indeed, the WB proﬁles from Nigerian sera are
not always typical of those seen with American
sera (data not shown).
Others have reported selective false-positive
results with Focus-HSV-2 tests in sera from
certain areas of Africa [18]. An inhibition assay
that is highly speciﬁc for HSV-2 antibodies has
shown that nearly 70% of discordant sera are
false-negative by WB [19]. Use of this inhibition
assay might help to resolve the issue of which test
is more accurate in the Nigerian population. In
addition, analyses of strain variability in African
HSV-2 isolates are in progress.
This study has several practical applications.
First, this is the ﬁrst wide-scale study, to our
knowledge, that shows the high reproducibility of
the Focus-HSV-2 test when positive sera are
repeated on different days. This ﬁnding suggests
that the antigen and the test components have
fairly close tolerances.
Second, the study indicates that standard tests,
while useful for comparing test performance, are,
at best, proxy measures of infection status. A true-
positive test should ideally be deﬁned as a
positive result in an infected patient. Thus, a
recent comparison showed that Focus and WB
tests were not fully concordant with respect to
detecting early seroconversion in culture-proven
HSV-2 cases: of 56 patients with primary genital
HSV-2 infection followed over time, four sero-
converted by Focus but not by WB, and four
seroconverted by WB but not by Focus [16]. These
ﬁndings imply that different sets of antibodies are
detected by each test. WB was validated among
sera from clinically deﬁned populations with
respect to HSV infection. The data from two
widely spaced studies have revealed that WB can
be falsely negative in early seroconversion [11,16].
Thus, it is critical to assess performance in terms
of the limitations and strengths of the standard
test. Ideally, new serological assays will be valid-
ated using clinical as well as serological criteria of
infection as the standard.
Third, it appears that the Focus assay has a high
PPV among populations with moderate HSV-2
seroprevalence (89–95% PPV in sites with
28–41% seropositive rates). These prevalences
approximate those reported in patients attending
sexually transmitted disease clinics in the USA
[20–24], a population for whom type-speciﬁc
testing has been recommended by the Centers
for Disease Control [25]. Thus, the test is likely to
be accurate for diagnosing HSV-2 infection in
patients at risk for genital herpes. NPVs ranged
from 94% to 100%, with a 98% NPV for all 675
sera tested.
Finally, these data and those reported else-
where [19,26] show that increasing the positive
cut-off to index values higher than 1.1 can
increase speciﬁcity. A cut-off of 3.5 increased the
speciﬁcity for HSV-2 to 96% (PPV 86%), but
decreased the sensitivity to 90% (NPV 98%).
False-positive test results are more likely to occur
in the low positive range of index values than
with index values > 5. In the present study, only
11 (26%) of 43 false-positive sera had index values
> 5.0. Low index values are more likely to occur in
early seroconversion than in established infection
[16]. Thus, patients with low index values for
HSV-2 (1.1–3.5) might be advised to return for
additional testing in 4–6 weeks to conﬁrm sero-
conversion or to have a different type-speciﬁc test
performed [27,28].
In summary, the Focus HerpeSelect ELISA tests
performed with high concordance to WB, with
notable geographical exceptions for HSV-1 in Thai
sites and for HSV-2 in Nigeria. Further study is
warranted to determine the cause of false-positive
tests in Nigeria, and the applicability of these data
to other African countries. Overall, the concor-
dance between the two Focus tests and the
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respective HSV-1 and HSV-2 WB results was high
(92%). While these ﬁndings cannot necessarily be
generalised to samples from men or to other
subgroups, it appears that the Focus assays are
sufﬁciently accurate for seroprevalence studies in
most geographical locations.
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